Published: 27. May, 2024
Cessatech A/S announces that the Safety Study 0202 has now been initiated with dosing…
Cessatech A/S announces that the Safety Study 0202 has now been initiated with dosing of the first patient.
- First patient has been dosed in Safety Study 0202 of lead candidate CT001.
- The Safety Study 0202 is an open-label, prospective study to assess safety, tolerability, analgesic effect, and feasibility of CT001 in 150 paediatric patients with moderate to severe pain, in the emergency setting.
- Cessatech expects the study to be completed by the end of 2024.